SITC

MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Health, Bone marrow, Annual general meeting, Charcot disease, European Medicines Agency, Maat, ICI, HSCT, Randomized controlled trial, CFO, ASH, Artificial intelligence, EMA, Patient, DSMB, PICASSO, Medi-Cal Access Program, Aryl hydrocarbon receptor, Hematopoietic stem cell transplantation, Immunotherapy, EUR, Therapy, Symantec Endpoint Protection, ORR, Cancer, Survival, MET, SITC, ARES, CGMP, Development, Society, Pharmaceutical industry, Vaccine, ALS

We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.

Key Points: 
  • We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.
  • MaaT Pharma reported revenues from its compassionate access program of EUR 0.4 million for the quarter ended September 30, 2023 comparable with the third quarter of 2022.
  • 2 The Company would like to correct a clerical error that was present in its Q2 results press release of July 27, 2023.
  • The EUR 0.9 million figure was the difference in revenue between H1 2023 and H1 2022 (EUR 1.4 million vs. EUR 0.5 million).

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

Retrieved on: 
Thursday, December 14, 2023
Entrepreneurship, Therapy, LNP, IND, Doctor of Pharmacy, Northwest Biotherapeutics, Patient, Myelocyte, Messenger, CARM, SITC, Doctor of Philosophy, Cancer, RNA, Pharmaceutical industry, Moderna, Mitsubishi Carisma

PHILADELPHIA, Dec. 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.

Key Points: 
  • This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need.
  • This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.
  • "The delivery of this first candidate demonstrates our ability to create novel in vivo CAR therapies that can be advanced toward the clinic.
  • We look forward to completing IND-enabling studies with the lead candidate and are excited about the prospect of bringing this therapy forward for patients with advanced solid tumors together with Moderna."

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

Retrieved on: 
Wednesday, December 6, 2023
KO, Research, Fertility, SAN, Hepatocellular carcinoma, Therapy, Natural killer T cell, Kis, Patient, NCR1, Tumor microenvironment, Regenerative medicine, GPC3, CISH, NK, Immunotherapy, Cancer, Survival, SITC, Partnership, HCC, Daily Naya Diganta, Neoplasm, FLEX, Society, Cell, AACR, Pharmaceutical industry, Vaccine

Specifically, the partnership will explore the combination of NAYA's GPC3-targeted NY-303 FLEX-NK™ bispecific antibody with ONK's ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy.

Key Points: 
  • Specifically, the partnership will explore the combination of NAYA's GPC3-targeted NY-303 FLEX-NK™ bispecific antibody with ONK's ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy.
  • NAYA and ONK plan to assess several combination therapies in preclinical cancer models in 2024 prior to subsequently exploring initiating clinical trials.
  • NAYA's FLEX-NK™ bispecific antibodies are built on a proprietary tetravalent, multifunctional format with flexible linker, facilitating simultaneous binding to different antigens on one or multiple cells.
  • ONK has exclusive, worldwide rights to KO of CISH in NK cells, regardless of the source of the NK cells.

Immunitas Therapeutics Announces Appointment of James Wooldridge as Chief Medical Officer and Upcoming Presentation at ASH 2023 Annual Meeting

Retrieved on: 
Monday, December 4, 2023
Acquisition, Therapy, ASH, CLEC2D, Immunoglobulin G, Biotechnology, Patient, Neoplasm, Checkmate, Hematology, Regeneron Pharmaceuticals, TLR9, Cancer, SITC, CMO, Bone marrow, Society, CD161, DSM-IV codes, Biology, NK, Drug development, Pharmaceutical industry, Vaccine

WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of James Wooldridge, M.D., as Chief Medical Officer (CMO). The company also announced it will present new data supporting continued clinical development of its lead program IMT-009 for solid tumors and hematological malignancies at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023).

Key Points: 
  • Seasoned biotech executive James Wooldridge, M.D., named Chief Medical Officer to support advancement of immuno-oncology pipeline
    WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of James Wooldridge, M.D., as Chief Medical Officer (CMO).
  • Dr. Wooldridge has served as Acting CMO since June 2023 and has been an advisor to the Company since October 2022.
  • "We are pleased to announce Jim's appointment as our Chief Medical Officer as we continue progressing toward our goal of providing groundbreaking therapeutic solutions for patients with cancer," said Amanda Wagner, Chief Executive Officer of Immunitas.
  • He previously served as the Chief Medical Officer at Checkmate Pharmaceuticals leading up to the company's acquisition by Regeneron.

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023
Science, Research, Solar eclipse of August 21, 2017, Therapy, Injection, Doctor of Philosophy, HGG, CD8, SITC, Disease, Risk, Annual general meeting, Cancer, Insurance, Break, Society for Immunotherapy of Cancer, MOS, CADL, Prostate cancer, Immune system, Antibody, Breast cancer, Pancreatic cancer, Biomarker, Safety, Patient, Administration, Cohort, Survivor, MD, Rated R, CA19-9, Development, Immunotherapy, Clinical trial, SOC, Arm, Society, Content discovery platform, Survival, Progression-free survival, HSV, HSV-1, Valaciclovir, Herpes simplex, Quarter, B cell, Vaccine, Pharmaceutical industry, NSCLC, Nature, Candel, PDAC, Fellow of the Academy of Medical Sciences

“We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.

Key Points: 
  • “We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.
  • Research and Development Expenses: Research and development expenses were $5.8 million for the third quarter of 2023 compared to $5.4 million for the third quarter of 2022.
  • Research and development expenses included non-cash stock compensation expense of $0.3 million for both the third quarter of 2023 and the third quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the third quarter of 2023 and the third quarter of 2022.

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Novartis Institute for Tropical Diseases, Research, Acute myeloid leukemia, Food, Disclosure, HIV disease progression rates, Syndrome, SITC, Annual general meeting, HCT, RIC, Society for Immunotherapy of Cancer, MDS, Neoplasm, KOL, Amgen, Cancer, Therapy, Patient, Food and Drug Administration, MAGE-C2, Acute leukemia, ASH, Heme, City, Immunotherapy, Clinical trial, Biomedical Research, PRAME, TCR, Society, HLA, Investigational New Drug, ALL, Haematopoietic system, FDA, Antigen, Trial of the century, IND, C2, Poster, Collection, Associate, AML, Vaccine, Security (finance), Pharmaceutical industry, Medical imaging, Hematology, Melanoma

WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results and provided a corporate update for the third quarter ended September 30, 2023.

Key Points: 
  • As of September 30, 2023, TScan Therapeutics had cash, cash equivalents, and marketable securities of $215.4 million, excluding $5.0 million of restricted cash.
  • Revenue for the third quarter ended September 30, 2023, was $3.9 million, compared to $3.4 million for the third quarter ended September 30, 2022 (2022 Quarter).
  • Research and development expenses for the third quarter ended September 30, 2023, were $22.7 million, compared to $15.0 million for the 2022 Quarter.
  • For the third quarter ended September 30, 2023, TScan Therapeutics reported a net loss of $23.0 million, compared to a net loss of $16.2 million for the 2022 Quarter.

Celyad Oncology reports third quarter 2023 financial results and recent business highlights

Retrieved on: 
Thursday, November 9, 2023
CD95, CAR, NKG2D, 2023 International Conference on Climate Resilient Pakistan, RNA, Graft-versus-host disease, Public expenditure, CD19, ICLE, Conference, PD-1, Autophagy, Research, Mont-Saint-Guibert, Nucleic acid, SITC, Immunotherapy, Intrinsic termination, MicroRNA, Fortification, Dumont, B-ALL, Gene, Society, Anti-CD19 immunotoxin, PSMA, Patient, BCMA, Lymphocyte, Vaccine, Bank, Medical device, Euronext

“Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.

Key Points: 
  • “Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.
  • Celyad Oncology has relocated from September 25, 2023 into a new research facility which fits better its current needs after the strategic shift.
  • The Company remains headquartered at the Axis Parc, Mont-Saint-Guibert, Belgium but with its new business location at Dumont 9.
  • Net cash burn during the third quarter of 2023 amounted to €2.7 million, in line with expectations.

23andMe Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
FDA, Research, African Americans, 23andMe, PGS, Health, Science, CORE (research service), Society for Immunotherapy of Cancer, Behavior, BRCA1, Consumer, Genetics, EBITDA, Workforce, Health Action International, Premium, Bangladesh Technical Education Board, Inflammation, BRCA2, DNA, Advertising, Pharmacokinetics, Consumer service, SITC, Science (journal), Immunotherapy, Database, Growth, Marketing, Webcast, GSK, GSK plc, Blood, Society, African, Total, Table, Pharmacogenomics, Harvard University, Lijun International Pharmaceutical (Holding) Co. Ltd., SAN, Pharmaceutical industry, Mobile phone, CD200R1, Simvastatin, Therapy

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.
  • Members of Total Health will also receive all the reports and features offered in our existing 23andMe+ Premium Membership.
  • Full year Adjusted EBITDA deficit is reaffirmed to be in the range of $180 to $160 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, November 8, 2023, to discuss the financial results for Q2 FY2024 and report on business progress.

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Food, Multiple myeloma, CXCR2, Enrollment, B-cell lymphoma, Lupus, SITC, Cetuximab, Annual general meeting, Rituximab, SLE, CAR, Hyperbaric treatment schedules, GAAP, Graft-versus-host disease, Safety, Cancer, Therapy, Ono Pharmaceutical, Investment, Patient, IPSC, Society for Immunotherapy of Cancer, Chronic lymphocytic leukemia, Research, Immunotherapy, TRAC, CD16, NK, Clinical trial, Multiplexing, BCL, Acute leukemia, CRS, Cell, FDA, Trastuzumab, IND, ONO, ADR, HER2, Neoplasm, Protocol, Lupus Research Alliance, Destiny, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, Tumor microenvironment, BCMA, Vaccine, Pharmaceutical industry, Autoimmunity

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • FT522 is the Company’s off-the-shelf, multiplexed-engineered natural killer (NK) cell product candidate that incorporates five synthetic controls of cell function.
  • In addition, as of September 30, 2023, cash receivables from the Company’s collaboration with ONO were $1.5 million.
  • Shares Outstanding: Common shares outstanding were 98.6 million, and preferred shares outstanding were 2.8 million, as of September 30, 2023.
  • ET to review financial and operating results for the quarter ended September 30, 2023.

Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

Retrieved on: 
Wednesday, November 8, 2023
Society for Immunotherapy of Cancer, Biomarker, Head, Publication, Akoya, Software, HNSCC, SITC, Instrument, Growth, Biotechnology, Immunotherapy, University, Total, HT, YTD, Rare-earth element, Video game, Lithium, Satellite navigation device, Cryptocurrency

MARLBOROUGH, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2023.

Key Points: 
  • Total revenue was $25.2 million in the third quarter of 2023, compared to $18.9 million in the prior year period; an increase of 34%.
  • Product revenue (which includes instruments, reagents, and software) was $18.0 million in the third quarter of 2023, compared to $14.4 million in the prior year period; an increase of 25%.
  • Service and other revenue totaled $7.2 million in the third quarter of 2023, compared to $4.4 million in the prior year period; an increase of 62%.
  • Akoya will host a conference call today, November 8, 2023, at 5:00 p.m. Eastern Time to discuss its third quarter 2023 financial results.